AstraZeneca (AZN)
Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death in EMERALD-3 Phase III trial
Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death in EMERALD-3 Phase III trial
📉 **NEGATIVE** • Medium confidence analysis (73%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (5%) **Content type:** Clinical